NVIDIA Corporation is a strong sell with a $27 price target by the end of 2027. Click here to read the latest analysis on ...

StoneCo shifts to credit/banking earnings with deposit funding and maturing loans. Read here for a detailed investment ...

Relative performance for nearly all LifeSmart Portfolios benefited from underweight exposure to fixed income and, for most ...

Cedar Creek was up 29.6%, net of fees and expenses, outperforming all the major indices we track. On the whole, as of the end ...

Berkshire Hathaway faces a less structurally advantaged, multipolar economic environment. Click here to find out why BRK.A ...

PKW performed almost as well as S&P 500 since its inception. Read why I consider PKW ETF worth buying for those who look for ...

Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea.

Cedar Creek Partners highlights the growth and adjusted earnings of ENDI Corp in its Q4 2025 update. Read the full analysis ...

Cedar Creek Partners details high-alpha returns in the expert market via positions like Exco Resources and Phi Group. Read ...

Despite deteriorating earnings revisions and weak growth, Accenture's profitability remains outstanding. Check out why ACN ...

Xenia Hotels & Resorts is upgraded to 'Buy' as shares appear undervalued and the balance sheet remains robust. Read more on ...

Nebius (NBIS) is a top 2026 AI stock pick—scalable GPU infrastructure poised to win as SaaS commoditizes. See growth, margin ...